363 related articles for article (PubMed ID: 19473409)
21. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
22. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
23. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Kroner PA; Foster PA; Fahs SA; Montgomery RR
Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
[TBL] [Abstract][Full Text] [Related]
24. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
25. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
26. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
27. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
Kao KJ; Pizzo SV; McKee PA
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
[TBL] [Abstract][Full Text] [Related]
28. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction.
Cacheris PM; Nichols WC; Ginsburg D
J Biol Chem; 1991 Jul; 266(21):13499-502. PubMed ID: 1906877
[TBL] [Abstract][Full Text] [Related]
30. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
Casonato A; Pontara E; Zerbinati P; Zucchetto A; Girolami A
Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
[TBL] [Abstract][Full Text] [Related]
31. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
J Thromb Haemost; 2023 Dec; 21(12):3477-3489. PubMed ID: 37726033
[TBL] [Abstract][Full Text] [Related]
32. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A.
Nichols TC; Bellinger DA; Reddick RL; Smith SV; Koch GG; Davis K; Sigman J; Brinkhous KM; Griggs TR; Read MS
Blood; 1993 May; 81(10):2644-51. PubMed ID: 8490173
[TBL] [Abstract][Full Text] [Related]
33. Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.
Takeyama M; Kasuda S; Sakurai Y; Shima M; Takeda T; Omura S; Naka H; Yoshioka A
Int J Hematol; 2007 Jun; 85(5):397-402. PubMed ID: 17562614
[TBL] [Abstract][Full Text] [Related]
34. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
[TBL] [Abstract][Full Text] [Related]
35. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
36. The disappearing act of factor VIII.
Lenting PJ; Christophe OD; Guéguen P
Haemophilia; 2010 May; 16(102):6-15. PubMed ID: 18771423
[TBL] [Abstract][Full Text] [Related]
37. The mutation Arg (53)----Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor.
Jorieux S; Tuley EA; Gaucher C; Mazurier C; Sadler JE
Blood; 1992 Feb; 79(3):563-7. PubMed ID: 1732004
[TBL] [Abstract][Full Text] [Related]
38. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
[TBL] [Abstract][Full Text] [Related]
39. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis and management of von Willebrand disease].
Higasa S; Tokugawa T; Sawada A
Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
